INCB050465 1.0 mg ( DrugBank: INCB050465 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
35天疱瘡1

35. 天疱瘡


臨床試験数 : 99 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002146-37-IT
(EUCTR)
20/03/201904/11/2020A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisA Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris - NA Pemphigus vulgaris
MedDRA version: 20.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: NA
Product Name: INCB050465 1.0 mg
Product Code: [NA]
INN or Proposed INN: INCB050465
Product Name: INCB050465 0.3 mg
Product Code: [NA]
INN or Proposed INN: INCB050465
Product Name: INCB050465 2.5mg
Product Code: [NA]
INN or Proposed INN: INCB050465 HYDROCHLORIDE
INCYTE CORPORATIONNULLNot RecruitingFemale: yes
Male: yes
18Phase 2France;Canada;Italy